Method for preparing nano liver-target biodegradating medicine carrier material

A carrier material and biodegradable technology, applied in the field of biomedical materials, to achieve good blood compatibility, good targeting ability, and improve the effect of treatment and quality of life

Inactive Publication Date: 2006-03-08
NANKAI UNIV
View PDF0 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The introduction of small molecular substances with high liver targeting properties such as glycyrrhetinic acid, glycyrrhizic acid, and bile acid into degradable and biocompatible polysaccharides and polyamino acids has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing nano liver-target biodegradating medicine carrier material
  • Method for preparing nano liver-target biodegradating medicine carrier material
  • Method for preparing nano liver-target biodegradating medicine carrier material

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Preparation of Glycyrrhetinic Acid-Modified Chitosan Nano Liver Targeted Biodegradation Drug Carrier Material:

[0051] 1.1 Preparation of Glycyrrhetinic Acid Modified Chitosan:

[0052] Weigh 2g of glycyrrhetinic acid and 1g of EDC into a 200mL beaker, add 70mL of DMF into the bottle, and magnetically stir to dissolve.

[0053] Add 5g of chitosan into a 500mL three-neck flask, add 100mL of distilled water and magnetically stir until dissolved. Then pour the glycyrrhetinic acid solution prepared above into the chitosan solution, continue stirring, and heat to 60° C. for 6 hours of reaction. The reaction solution was cooled to 40°C and concentrated to about 50 mL with a rotary evaporator. Pour the concentrated solution into a beaker filled with 800mL ethanol to precipitate, filter, wash the precipitate with 50mL ethanol and 50mL ether respectively, and vacuum dry (40°C, 5mmHg) for 24 hours. The product contains 5% glycyrrhetinic acid.

[0054] 1.2 Preparatio...

Embodiment 2

[0060] Example 2 Preparation of polylysine nano liver targeted biodegradation drug carrier material modified with glycyrrhetinic acid:

[0061] 2.1 Preparation of glycyrrhetinic acid modified polylysine:

[0062] Weigh 2g of glycyrrhetinic acid and 1g of EDC into a 200mL beaker, add 70mL of DMF into the bottle, and magnetically stir to dissolve.

[0063] Add 5g polylysine into a 500mL three-neck flask, add 100mL distilled water and magnetically stir until dissolved. Then pour the glycyrrhetinic acid solution prepared above into the polylysine solution, continue stirring, and heat to 60° C. for 6 hours. The reaction solution was cooled to 40°C and concentrated to about 50 mL with a rotary evaporator. Pour the concentrated solution into a beaker filled with 800mL ethanol to precipitate, filter, wash the precipitate with 50mL ethanol and 50mL ether respectively, and vacuum dry (40°C, 5mmHg) for 24 hours. The product contains 8% glycyrrhetinic acid.

[0064] 2.2 Preparation of ...

Embodiment 3

[0070] Example 3 Preparation of agar nano liver targeted biodegradation drug carrier material modified with glycyrrhetinic acid:

[0071] 3.1 Preparation of Glycyrrhetinic Acid Modified Agar:

[0072] Weigh 2g of glycyrrhetinic acid and 1g of EDC into a 200mL beaker, add 70mL of DMF into the bottle, and magnetically stir to dissolve.

[0073] Add 7g of agar into a 500mL three-neck flask, add 100mL of DMF and magnetically stir until dissolved. Then pour the glycyrrhetinic acid solution prepared above into the agar solution, continue to stir, and heat to 60° C. for 6 hours to react. The reaction solution was cooled to 40°C and concentrated to about 50 mL with a rotary evaporator. Pour the concentrated solution into a beaker filled with 800mL ethanol to precipitate, filter, wash the precipitate with 50mL ethanol and 50mL ether respectively, and vacuum dry (40°C, 5mmHg) for 24 hours. The product contains 4% glycyrrhetinic acid.

[0074] 3.2 Preparation of Glycyrrhetinic Acid Mo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
degree of substitutionaaaaaaaaaa
Login to view more

Abstract

The preparation method includes the following steps: modifying hepatic target compound onto degradable polymer (chitosan, polylysine, glucosan, agar, polyglutamic acid-benzyl ester, polyalanine) with biological compatibility, and adopting ion exchange or ultrasonic emulsification process to obtain the invented nano hepatic target bio-degradable medicine carrier material. The hepatic target nano particle solution has good target performance for liver, the medicine enriched rate in the liver can be up to 75%, and its slowly-released administration can be up to above 15 days.

Description

technical field [0001] The invention belongs to the field of biomedical materials, in particular to a method for preparing a nano liver-targeted biodegradation drug carrier material. Background technique [0002] Liver cancer, especially primary liver cancer, is a common clinical disease and frequently-occurring disease. The mortality rate of primary liver cancer ranks third among malignant tumors, second only to gastric cancer and esophageal cancer. my country is an area with a high incidence of liver cancer, accounting for more than 50% of the global incidence. For the treatment of liver cancer, liver transplantation is the most recommended at present, but donors are hard to find. Anticancer drug therapy (cyclophosphamide, arabinothymidine hydrochloride) due to the systemic distribution of the drug, the drug concentration in the lesion is not high enough, but the damage to other organs is greater, and some patients often die from the damage of chemotherapy drugs to other...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/36A61K47/30A61K47/48A61K31/704A61K31/575A61K31/56A61P35/00A61K47/61A61K47/64
Inventor 袁直查瑞涛杜田赵建新
Owner NANKAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products